AGMB
NASD AgomAb Therapeutics NV ADR$8.28 ↑ +0.00 (+0.00%) Trading Up from the previous close of $8.28, $0.25 below the day’s high of $8.53
- YTD change
- -43.48%
- vs 20-day SMA
- -15.43%
- vs 200-day SMA
- N/A
Price ranges
Price & Performance
-2.87 (-25.62%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 53.5% away from all-time highs of $17.82
- AGMB is down 43% since the beginning of the year
- AGMB is down 43% over the past 12 months
- AGMB is down 31% over the past 1 month
- 3% of all AGMB investors are betting against AGMB
AGMB reads poor: the 12-month move is -43.1%.
- Previous minute
- +$0.00
- Last hour
- +$0.00
- Last 5 days
- -10.20%
- vs 8-day SMA
- -6.52%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases. Its mission is to develop disease-modifying therapeutics that aim to resolve fibrosis and restore organ function, enabling patients with these disorders to live fuller and healthier lives. The company was founded by Paolo Michieli, Manuela Cazzanti, Virginia Morello, Federica Caterina Linty, Michael Potter Saunders, and Hans J. W. de Haard in 2017 and is headquartered in Ghent, Belgium.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
